Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Cancer Epigenomics

Benjamin Ebert

本杰明·埃伯特

MD, PhD

🏢Dana-Farber Cancer Institute / Harvard Medical School(达纳-法伯癌症研究所 / 哈佛医学院)🌐USA

Chair, Department of Medical Oncology; George P. Canellos MD Professor of Medicine肿瘤内科系主任;乔治·卡内洛斯医学教授

85
h-index
3
Key Papers
4
Awards
3
Key Contributions

👥Biography 个人简介

Benjamin Ebert is a world leader in clonal hematopoiesis and the epigenetic basis of myeloid malignancies. His research has defined the mutational landscape of MDS and AML, elucidated how TET2, DNMT3A, and splicing factor mutations drive clonal expansion and malignant transformation, and identified novel therapeutic strategies.

Share:

🧪Research Fields 研究领域

Clonal Hematopoiesis克隆性造血
TET2 and DNMT3A MutationsTET2和DNMT3A突变
Myelodysplastic Syndromes骨髓增生异常综合征
Splicing Factor Mutations剪接因子突变
Leukemia Epigenetics白血病表观遗传学

🎓Key Contributions 主要贡献

Clonal Hematopoiesis Biology and Risk

Performed landmark studies defining the prevalence, mutational drivers, and cardiovascular and malignancy risks of clonal hematopoiesis of indeterminate potential (CHIP), establishing it as a major aging-related risk factor.

TET2 and DNMT3A in Myeloid Transformation

Characterized how TET2 loss and DNMT3A mutations alter hematopoietic stem cell self-renewal programs through aberrant DNA methylation and hydroxymethylation, promoting clonal dominance and MDS/AML evolution.

Splicing Factor Mutations in MDS

Defined recurrent somatic mutations in splicing factors (SF3B1, SRSF2, U2AF1) as key epigenetic-adjacent drivers of MDS, explaining how dysregulated splicing disrupts chromatin regulatory gene networks.

Representative Works 代表性著作

[1]

Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease

New England Journal of Medicine (2017)

Demonstrated that CHIP mutations in TET2 and DNMT3A increase cardiovascular disease risk through epigenetic dysregulation of inflammatory macrophages.

[2]

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

Nature (2015)

Revealed mechanism of lenalidomide in MDS, showing it acts as a molecular glue degrader targeting CK1α via CRBN E3 ligase.

[3]

Somatic mutations in hematopoietic stem and progenitor cells and their role in the development of cancer

Cell Stem Cell (2019)

Comprehensive review of somatic mutation accumulation in HSCs and how epigenetic drivers initiate clonal hematopoiesis and malignancy.

🏆Awards & Recognition 奖项与荣誉

🏆ASH Henry M. Stratton Medal
🏆AACR Outstanding Investigator Award
🏆Howard Hughes Medical Institute Investigator
🏆National Academy of Medicine Member

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 本杰明·埃伯特 的研究动态

Follow Benjamin Ebert's research updates

留下邮箱,当我们发布与 Benjamin Ebert(Dana-Farber Cancer Institute / Harvard Medical School)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment